Subtype 1.4 is associated with aberrations in both the MAPK and CDK pathways, specifically activation of BRAF and over-expression of CCND1/Cyclin D. The CDK pathway has been suggested to contribute to metastasis of melanoma with BRAF mutations. Here, CCND1 is linked to melanoma.